Alzheimer Portugal’s project, Memo e Kelembra nas Escolas (Memo and Kelembra in schools) arose from a need to sensitise and raise awareness among the population – particularly children, teachers and assistants – about Alzheimer’s disease (AD) and other dementias, as well as their implications for our society, in particular families.
EPAD is mainly sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU). The EPAD programme has an initial budget of €64M distributed across a total of 36 partners from the private and academic sectors.
35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia
Paris, January 15, 2015 The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.
Previous attempts to bring new drugs for Alzheimer’s disease to the market have been disappointing despite a high level of investment. However, the realisation that Alzheimer’s disease is a progressive disorder and that early intervention may be more effective has led to research efforts being focused on prevention. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities as identified by specific tests), who still may have little or no complaints or clinical symptoms.